Actinium Pharmaceuticals Launches Actinium-225 Focused Strategic Initiative to Leverage Proprietary Cyclotron Based Manufacturing Technology to Address Growing Market Demand

Actinium's cyclotron produced Actinium-225 material has demonstrated radiochemical and radionuclidic purity identical to current gold-standard methods and has the potential to be significantly lower cost at commercial scale than currently available production methods  Proprietary manufacturing technology supported by 5 issued U.S. patents, 49 issued international patents and significant technical know-how Actinium to commit to multi-million-dollar investment and pursue collaborations on a global basis to s ...